Primary research interest

Development of vaccines and immunostimulators

About me

I have a Master/Engineer degree in Biotechnology and a PhD in Chemistry from Wroclaw University of Technology, Poland. I did my initial postdoctoral training at Tokushima Bunri University (Japan), and then I was awarded with Japan Society for the Promotion of Science Postdoctoral Fellowship to work in the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University (Japan) to study prodrugs of paclitaxel. I also co-developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid-phase peptide synthesis and these units have been commercialized by Merck-Novabiochem. I moved to Australia to work in Prof. Istvan Toth’s group in 2008 and I was appointed as a Strategic Fund Research Fellow by The University of Queensland in 2010 to work on the vaccine delivery systems. I serve on several editorial boards, including Frontiers in Pharmacology as an Associate Editor and Vaccines as a Regional Editor of Australia. Finally, I was just recently awarded with Higher Education Academy (HEA) Fellowship (2023).

Research focus and collaborations

My research interest is related mostly to vaccine development, which involves organic and medicinal chemistry, peptide and macromolecule synthesis, self-assembly, and other techniques involved in nanoparticle formation, as well as liposomal and polymer-based delivery systems. My work focuses on vaccine and antibiotic design, their characterisation, and in vitro and in vivo evaluation.

I am involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria, tuberculosis, cancer (mainly HPV-related), and fertility control vaccines along with antibiotics against multidrug-resistant bacteria. This collaborative work involved such universities as Griffith University (Gold Coast), James Cook University (Cairns), Royal Melbourne Institute of Technology (Melbourne), and Translation Research Institute (Brisbane); Istituto Zooprofilattico Sperimentale del Mezzogiorno (Italy), Lodz University of Technology (Poland), National University of Malaysia (Malaysia), and Washington University School of Medicine (USA).

Funded projects

2024-2027 NHMRC Ideas Grant - A nanovaccine against Invasive Group A Streptococcus and Rheumatic Heart Disease ($608,061)

2024-2027 NHRMC Ideas Grant - Paving the way for a Clinical Vaccine Candidate against Hookworm Infection ($855,524)

2024-2025  Australia’s Economic Accelerator Launch Program - Single-shot anti-fertility vaccine in pigs. ($471,683)

2021-2024  Meat & Livestock Australia Limited - A single-shot fertility vaccine in cattle. ($850,733)

2021-2024  ARC Discovery Project - Poly(amino acids) as immune stimulators. ($425,000)

2020-2021  NHMRC Development grant - Hookworm peptide therapeutic for oral treatment of IBD. ($732,700)  

2011-2014  NHMRC Project grant - A self-assembling and self-adjuvanting nanoparticular therapeutic vaccine against cervical cancer. ($374,208)

Teaching interests

Medicinal chemistry, vaccine and drug development

Achievements and awards

I was ranked third in the world in the Subunit Vaccines field (2012-2022). Expertscape's PubMed-based scheme labelled me as a "World Expert" and placed me in the top 0.1% of scholars writing about Subunit Vaccines over the past 10 years: “The expertise of Mariusz Skwarczynski ranks in the Top 0.022% of 18,308 published authors worldwide on Subunit Vaccines from 2012 through 2022 (3rd in the world).” https://expertscape.com/ex/vaccines%2C+subunit

I was listed among World’s Top 1% Scientists by Stanford University (2022 ranking, all science fields) for its activity in 2021 and among World’s Top 2% Scientists in whole carrier ranking (years 1788-2021). https://elsevier.digitalcommonsdata.com/datasets/btchxktzyw

Featured publications

1. Koirala, P.; Chen, S.-P. R.; Boer, J. C.; Khalil, Z. G.; Deceneux, C.; Goodchild, G.; Lu, L.; Faruck, M. O.; Shalash, A. O.; Bashiri, S.; Capon, R. J.; Hussein, W. M.; Monteiro, M. J.; Plebanski, M.; Toth, I.; Skwarczynski, M. Polymeric Nanoparticles as a Self-Adjuvanting Peptide Vaccine Delivery System: The Role of Shape. Adv. Funct. Mater. 2023, 2209304. (Impact Factor = 19.924)

2. Shalash, A. O.; Becker, L.; Yang, J.; Giacomin, P.; Pearson, M.; Hussein, Loukas, A.; Toth, I.; Skwarczynski, M. Development of a Peptide Vaccine against Hookworm Infection: Immunogenicity, Efficacy, and Immune Correlates of Protection, J. Allergy Clin. Immunol. 2022, 150, 157-169.e10. (Impact Factor = 14.290)

3. Alharbi, N; Skwarczynski, M.; Toth, I. The Influence of Component Structural Arrangement on Peptide Vaccine Immunogenicity. Biotechnology Advances, 2022, 60, 107029. (Impact Factor = 17.681)

4. Nahar, U. J.; Toth, I.; Skwarczynski, M. Mannose in vaccine delivery. J. Control. Release 2022, 351, 284-300. (Impact Factor = 11.467)

5. Azuar A, Li Z, Shibu MA, Zhao L, Luo Y, Shalash AO, Khalil ZG, Capon RJ, Hussein WM, Toth I, Skwarczynski, M. Poly(hydrophobic amino acid)-based self-adjuvanting nanoparticles for Group A Streptococcus vaccine delivery. J. Med. Chem., 2021, 64, 2648-2658. (Impact Factor = 8.039)

6. Al-Nazal, H. A.; Cooper, E.; Ho, M. F.; Eskandari, S.; Majam, V. F.; Giddam, A. K.; Hussein, W. M.; Islam, M. T.; Skwarczynski, M.; Toth, I.; Kumar, S.; Zaid, A.; Batzloff, M.; Stanisic, D. I.; Good M. F. Pre-clinical evaluation of a whole-parasite vaccine to control human babesiosis. Cell Host Microbe, 2021, 29, 894-903. (Impact Factor = 31.316)

7. Shalash, A. O; Hussein, W. M.; Skwarczynski, M.; Toth, I. Key considerations for the development of safe and effective SARS-CoV-2 subunit vaccine: A peptide-based vaccine alternative. Advanced Science, 2021, 2100985. doi: 10.1002/advs.202100985 (Impact Factor = 17.521)

8. Bartlett, S.; Eichenberger, R. M.; Nevagi, R. J.; Ghaffar, K. A.; Marasini, N.; Dai, Y.; Loukas, A.; Toth, I.; Skwarczynski, M. Lipopeptide-based oral vaccine against hookworm infection. J. Infect. Dis. 2020, 221, 934–942. (Impact Factor = 7.759)

9. Skwarczynski, M.; Zhao, G.; Boer, J. C.; Ozberk, V.; Azuar, A.; Cruz, J. G.; Giddam, A. K.; Khalil, Z. G.; Pandey, M.; Shibu, M. A.; Hussein, W. M.; Nevagi, R. J.; Batzloff, M. R.; Wells, J. W.; Capon, R. J.; Plebanski, M.; Good, M. F.; Toth I. Poly(amino acids) as a Potent Self-adjuvanting Delivery System for Peptide-based Nanovaccines Science Advances 2020, 6, eaax2285. (Impact Factor = 14.957)

10. Azuar, A.; Zhao, L.; Hei, T. T.; Nevagi, R. J.; Bartlett, S.; Hussein, W. M.; Khalil, Z. G.; Capon, R. J.; Toth I.; Skwarczynski, M. Cholic Acid-based Delivery System for Vaccine Candidates against Group A Streptococcus. ACS Med. Chem. Lett., 2019, 10, 1253-1259. (Impact Factor = 4.632)

Researcher biography

Mariusz Skwarczynski completed his Ph.D. in Chemistry in 1999 at Wroclaw University of Technology (Poland). His postdoctoral training began at Tokushima Bunri University (Japan) under the direction of late Professor M. Nishizawa, where he studied the biomimetic total synthesis of anticancer agent paclitaxel. He then joined the laboratory of Professor Yoshiaki Kiso at Kyoto Pharmaceutical University (Japan) to study prodrugs of paclitaxel. In 2004 he was awarded with Japanese fellowship (Japan Society for the Promotion of Science postdoctoral fellowship) and research grant to conduct further research on paclitaxel. He developed novel classes of paclitaxel prodrugs: isotaxoids and phototaxels. He also co-developed an epimerization-free method for the synthesis of novel building blocks (isodipeptides) for solid phase peptide synthesis and these units have been commercialized by Merck-Novabiochem.

In 2008 he joined Professor Istvan Toth group at University of Queensland (Australia) to work on vaccine delivery strategies. Since then, he research is mainly focused on nanotechnology-based peptide vaccine delivery approaches. In 2010 he was awarded with University of Queensland Strategic Fund Research Fellowship. In Australia, he is involved in a wide range of collaborative research projects, both nationally and internationally, to develop vaccines against GAS, HIV, hookworm infections, malaria and cancer, along with antibiotics against multidrug resistant bacteria.